{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:24Z","timestamp":1792800864461,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China Youth Project","award":["81900131"],"award-info":[{"award-number":["81900131"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Tianjin Municipal Natural Science Foundation","award":["18JCQNJC80400"],"award-info":[{"award-number":["18JCQNJC80400"]}]},{"name":"Tianjin Education Commission Research Project","award":["2018KJ043"],"award-info":[{"award-number":["2018KJ043"]}]},{"name":"Medjaden Academy and Research Foundation for Young Scientists","award":["MJR20221011"],"award-info":[{"award-number":["MJR20221011"]}]},{"name":"The youth project of Tianjin Health and wellness Commission","award":["TJWJ2021QN001"],"award-info":[{"award-number":["TJWJ2021QN001"]}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"crossref","award":["20YFZCSY00060"],"award-info":[{"award-number":["20YFZCSY00060"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Key Medical Discipline(Specialty) Construction project","award":["TJYXZDXK-028A"],"award-info":[{"award-number":["TJYXZDXK-028A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myelodysplastic syndrome (MDS) is a clonal disease of hematopoietic cells, characterized by hematopoietic cell hematopoiesis and a high risk of transformation into acute myeloid leukemia (AML). Although the underlying mechanism is unclear, MDS is often associated with immune system disorders, especially cellular immune abnormalities. We analyzed the number of lymphocyte subsets by flow cytometry assay and explored the alteration of lymphocyte subsets in MDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Healthy controls, inpatients with primary MDS and patients with AML diagnosed from January 2017 to July 2021 were included. Flow cytometry assays were used to study lymphocyte subsets obtained from the bone marrow of the participants as well as changes in natural killer (NK) cell function. One-way analysis of variance and Student\u2019s t-test were used to analyze the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found a reduction in the number and function of NK cells in patients with MDS. By further measuring the activating and inhibitory receptors on the surface of NK cells, we found that the T cell immunoglobulin and ITIM domain (TIGIT) was the highest expressed marker on NK cells. Additionally, the expression of CD155, which is the ligand of TIGIT, was significantly higher than expressions of CD112 and CD113 on bone marrow mesenchymal stem cells (BMSCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The co-culture results of BMSCs and NK cells demonstrated that BMSCs regulate NK cells through the TIGIT\/CD155 interaction, indicating that NK cells play a vital role in MDS progression. BMSCs regulate the function of NK cells via TIGIT\/CD155.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-022-00985-2","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T11:22:46Z","timestamp":1666869766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes"],"prefix":"10.1186","volume":"20","author":[{"given":"Zhaoyun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"985_CR1","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/cncr.22570","volume":"109","author":"X Ma","year":"2007","unstructured":"Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536\u201342. https:\/\/doi.org\/10.1002\/cncr.22570.","journal-title":"Cancer"},{"key":"985_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0145-2126(02)00098-X","volume":"27","author":"DP Steensma","year":"2003","unstructured":"Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95\u2013120. https:\/\/doi.org\/10.1016\/S0145-2126(02)00098-X.","journal-title":"Leuk Res"},{"key":"985_CR3","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.pathol.2017.12.104","volume":"50","author":"M Collin","year":"2018","unstructured":"Collin M. Haematopoietic and immune defects associated with GATA2 mutation. Pathology. 2018;50:S44. https:\/\/doi.org\/10.1016\/j.pathol.2017.12.104.","journal-title":"Pathology"},{"issue":"9","key":"985_CR4","first-page":"10840","volume":"8","author":"W Zhang","year":"2015","unstructured":"Zhang W, Shao Z, Fu R, Wang H, Li L, Liu H. Down-regulation of TET2 in CD3+ and CD34+ cells of myelodysplastic syndromes and enhances CD34+ cells proliferation. Int J Clin Exper Pathol. 2015;8(9):10840.","journal-title":"Int J Clin Exper Pathol"},{"key":"985_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0145-2126(01)00083-2","volume":"25","author":"DE Epperson","year":"2001","unstructured":"Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001;25:1075\u201383. https:\/\/doi.org\/10.1016\/S0145-2126(01)00083-2.","journal-title":"Leuk Res"},{"key":"985_CR6","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1182\/blood-2004-10-4045","volume":"106","author":"MW Wlodarski","year":"2005","unstructured":"Wlodarski MW, O\u2019Keefe C, Howe EC, Risitano AM, Rodriguez A, Warshawsky I, Loughran TP Jr, Maciejewski JP. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005;106:2769\u201380. https:\/\/doi.org\/10.1182\/blood-2004-10-4045.","journal-title":"Blood"},{"key":"985_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.08.016","author":"C Fozza","year":"2016","unstructured":"Fozza C, Dore F, Isoni MA, Crobu V. The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol. 2016. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.016.","journal-title":"Crit Rev Oncol Hematol"},{"key":"985_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fonc.2016.00172","volume":"6","author":"C Lambert","year":"2016","unstructured":"Lambert C, Wu Y, Aanei C. Bone marrow immunity and myelodysplasia. Front Oncol. 2016;6:172. https:\/\/doi.org\/10.3389\/fonc.2016.00172.","journal-title":"Front Oncol"},{"key":"985_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/asheducation-2002.1.136","volume":"2002","author":"PL Greenberg","year":"2002","unstructured":"Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology. 2002;2002:136\u201361. https:\/\/doi.org\/10.1182\/asheducation-2002.1.136.","journal-title":"Hematology"},{"key":"985_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(84)90147-4","author":"G Kerndrup","year":"1984","unstructured":"Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leukemia research. 1984. https:\/\/doi.org\/10.1016\/0145-2126(84)90147-4.","journal-title":"Leukemia research"},{"key":"985_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320191","author":"F Porzsolt","year":"1982","unstructured":"Porzsolt F, Heimpel H. Impaired T-cell and NK-cell function in patients with preleukemia. Blut. 1982. https:\/\/doi.org\/10.1007\/BF00320191.","journal-title":"Blut"},{"key":"985_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(83)90103-0","author":"RW Anderson","year":"1983","unstructured":"Anderson RW, Volsky DJ, Greenberg B, Knox SJ, Bechtold T, Kuszynski C, Harada S, Purtilo DT. Lymphocyte abnormalities in preleukemia\u2013I. decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leukemia Res. 1983. https:\/\/doi.org\/10.1016\/0145-2126(83)90103-0.","journal-title":"Leukemia Res"},{"issue":"1","key":"985_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annual Rev Immunol. 2005;23(1):225\u201374.","journal-title":"Annual Rev Immunol"},{"key":"985_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1074-7613(00)70060-4","volume":"4","author":"A Shibuya","year":"1996","unstructured":"Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573\u201381. https:\/\/doi.org\/10.1016\/S1074-7613(00)70060-4.","journal-title":"Immunity"},{"key":"985_CR15","doi-asserted-by":"publisher","first-page":"15627","DOI":"10.1038\/ncomms15627","volume":"8","author":"AK Wagner","year":"2017","unstructured":"Wagner AK, Kadri N, Snall J, Brodin P, Gilfillan S, Colonna M, Bernhardt G, Hoglund P, Karre K, Chambers BJ. Expression of CD226 is associated to but not required for NK cell education. Nat Commun. 2017;8:15627. https:\/\/doi.org\/10.1038\/ncomms15627.","journal-title":"Nat Commun"},{"key":"985_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0161-5890(01)00107-9","volume":"38","author":"F Borrego","year":"2002","unstructured":"Borrego F, Kabat J, Kim D-K, Lieto L, Maasho K, Pe\u00f1a J, Solana R, Coligan JE. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002;38:637\u201360. https:\/\/doi.org\/10.1016\/S0161-5890(01)00107-9.","journal-title":"Mol Immunol"},{"key":"985_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nature Immunol. 2018. https:\/\/doi.org\/10.1038\/s41590-018-0132-0.","journal-title":"Nature Immunol"},{"key":"985_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38:20\u20138. https:\/\/doi.org\/10.1016\/j.it.2016.10.002.","journal-title":"Trends Immunol"},{"key":"985_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/08820139.2016.1237524","volume":"46","author":"X-G Liu","year":"2017","unstructured":"Liu X-G, Hou M, Liu Y. TIGIT, a novel therapeutic target for tumor immunotherapy. Immunol Invest. 2017;46:172\u201382. https:\/\/doi.org\/10.1080\/08820139.2016.1237524.","journal-title":"Immunol Invest"},{"key":"985_CR20","doi-asserted-by":"publisher","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","volume":"289","author":"M Li","year":"2014","unstructured":"Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem. 2014;289:17647\u201357. https:\/\/doi.org\/10.1074\/jbc.M114.572420.","journal-title":"J Biol Chem"},{"key":"985_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B, Fan Z. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20:456\u201364. https:\/\/doi.org\/10.1038\/cdd.2012.141.","journal-title":"Cell Death Differ"},{"key":"985_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nature Immunol. 2009;10:48\u201357. https:\/\/doi.org\/10.1038\/ni.1674.","journal-title":"Nature Immunol"},{"key":"985_CR23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903474106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proceed Nat Acad Sci. 2009. https:\/\/doi.org\/10.1073\/pnas.0903474106.","journal-title":"Proceed Nat Acad Sci"},{"key":"985_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh059","author":"S Tahara-Hanaoka","year":"2004","unstructured":"Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, Honda SI, Lanier LL, Shibuya A. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2\/CD112). Int Immunol. 2004. https:\/\/doi.org\/10.1093\/intimm\/dxh059.","journal-title":"Int Immunol"},{"key":"985_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.17","volume":"5","author":"JC Huang","year":"2015","unstructured":"Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015;5: e302. https:\/\/doi.org\/10.1038\/bcj.2015.17.","journal-title":"Blood Cancer J"},{"key":"985_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7: e2062. https:\/\/doi.org\/10.1038\/cddis.2015.327.","journal-title":"Cell Death Dis"},{"key":"985_CR27","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood-2005-07-2775","volume":"107","author":"GM Spaggiari","year":"2006","unstructured":"Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484\u201390. https:\/\/doi.org\/10.1182\/blood-2005-07-2775.","journal-title":"Blood"},{"key":"985_CR28","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2004-0359","author":"PA Sotiropoulou","year":"2006","unstructured":"Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006. https:\/\/doi.org\/10.1634\/stemcells.2004-0359.","journal-title":"Stem Cells"},{"key":"985_CR29","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3109\/10428194.2011.584002","volume":"52","author":"ED Warlick","year":"2011","unstructured":"Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma. 2011;52:2045\u20139. https:\/\/doi.org\/10.3109\/10428194.2011.584002.","journal-title":"Leuk Lymphoma"},{"key":"985_CR30","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00018-015-1846-x","volume":"72","author":"L Yang","year":"2015","unstructured":"Yang L, Qian Y, Eksioglu E, Epling-Burnette PK, Wei S. The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015;72:1959\u201366. https:\/\/doi.org\/10.1007\/s00018-015-1846-x.","journal-title":"Cell Mol Life Sci"},{"key":"985_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2004.07.007","author":"T Sakisaka","year":"2004","unstructured":"Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Current Opin Cell Biol. 2004. https:\/\/doi.org\/10.1016\/j.ceb.2004.07.007.","journal-title":"Current Opin Cell Biol"},{"key":"985_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723\u201332. https:\/\/doi.org\/10.1038\/s41590-018-0132-0.","journal-title":"Nat Immunol"},{"key":"985_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2031-x","author":"F Xu","year":"2017","unstructured":"Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol. 2017. https:\/\/doi.org\/10.1007\/s00262-017-2031-x.","journal-title":"Cancer Immunol"},{"key":"985_CR34","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2017.03.036","author":"SJ Xu","year":"2017","unstructured":"Xu SJ, Shao ZH, Fu R, Wang HQ, Liu H, Liu CY, Zhang W. Subtype and functional biomarker changes of NK cells in peripheral blood of patients with myelodysplastic syndrome. Zhongguo shi yan xue ye xue za zhi. 2017. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.2017.03.036.","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"985_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF01697982","volume":"71","author":"O Iwase","year":"1995","unstructured":"Iwase O, Aizawa S, Kuriyama Y, Yaguchi M, Nakano M, Toyama K. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. Ann Hematol. 1995;71:293\u20139. https:\/\/doi.org\/10.1007\/BF01697982.","journal-title":"Ann Hematol"},{"key":"985_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/cancers11060877","volume":"11","author":"B Sanchez-Correa","year":"2019","unstructured":"Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Ba\u00f1as H, Casas-Avil\u00e9s I, Dur\u00e1n E, et al. DNAM-1 and the TIGIT\/PVRIG\/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers. 2019;11:877. https:\/\/doi.org\/10.3390\/cancers11060877.","journal-title":"Cancers"},{"key":"985_CR37","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895\u2013699895. https:\/\/doi.org\/10.3389\/fimmu.2021.699895.","journal-title":"Front Immunol"},{"key":"985_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155\u2013155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2.","journal-title":"Mol Cancer"},{"key":"985_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/nature08851","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, Aung Z. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. Nature. 2010. https:\/\/doi.org\/10.1038\/nature08851.","journal-title":"Nature"},{"key":"985_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.02.014","author":"H Medyouf","year":"2014","unstructured":"Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014. https:\/\/doi.org\/10.1016\/j.stem.2014.02.014.","journal-title":"Cell Stem Cell"},{"key":"985_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2015.10.005","author":"G Falconi","year":"2016","unstructured":"Falconi G, Fabiani E, Fianchi L, Criscuolo M, Raffaelli CS, Bellesi S, Hohaus S, Voso MT, D\u2019Al\u00f2 F, Leone G. Impairment of PI3K\/AKT and WNT\/\u03b2-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Exper Hematol. 2016. https:\/\/doi.org\/10.1016\/j.exphem.2015.10.005.","journal-title":"Exper Hematol"},{"key":"985_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057470","author":"Z Wang","year":"2013","unstructured":"Wang Z, Tang X, Xu W, Cao Z, Sun L, Li W, Li Q, Zou P, Zhao Z. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PloS one. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0057470.","journal-title":"PloS one"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-00985-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-022-00985-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-00985-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T19:40:55Z","timestamp":1691610055000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-022-00985-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1186\/s12964-022-00985-2","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This cohort study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of Tianjin Medical University General Hospital (NO.IRB2021-WZ-180).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report that there are no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}